Molecular Imaging and Biology

, Volume 12, Issue 1, pp 85–88 | Cite as

PET/CT in the Evaluation of Inflammatory Bowel Disease: Studies in Patients Before and After Treatment

  • Bret J. Spier
  • Scott B. Perlman
  • Christine J. Jaskowiak
  • Mark Reichelderfer
Research Article

Abstract

Purpose

The purpose of this study was to evaluate the appropriate 2-deoxy-2-[18F]fluoro-d-glucose–positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity.

Procedures

We performed PET–computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0–3) for the appropriate FDG-PET determination.

Results

There were five patients [Crohn’s disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77–807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001).

Conclusion

Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.

Key words

Treatment PET/CT Inflammatory bowel disease Crohn’s colitis Ulcerative colitis 

Notes

Acknowledgment

This study was funded in part by an unrestricted grant from Procter & Gamble Pharmaceuticals.

Conflict of interest

None of the authors have conflicts of interest to disclose.

References

  1. 1.
    Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K (1999) 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 354:836–837 (PMID: 10485733)PubMedGoogle Scholar
  2. 2.
    Lemberg DA, Issenman RM, Cawdron R et al (2005) Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11:733–738 (PMID 16043988)CrossRefPubMedGoogle Scholar
  3. 3.
    Neurath MF, Vehling D, Schunk K et al (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978–1985 (PMID: 12190164)CrossRefPubMedGoogle Scholar
  4. 4.
    Pio BS, Byrne FR, Aranda R et al (2003) Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-d-glucose-labeled white blood cells. Mol Imaging Biol 5:271–277 (PMID: 14499142)CrossRefPubMedGoogle Scholar
  5. 5.
    Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072:379–385 (PMID: 17057218)CrossRefPubMedGoogle Scholar
  6. 6.
    Meisner RS, Spier BJ, Einarsson S et al (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993–1000 (PMID: 17394243)CrossRefPubMedGoogle Scholar
  7. 7.
    Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R (2007) Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 48:1053–1059 (PMID: 17574978)CrossRefPubMedGoogle Scholar
  8. 8.
    Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 70:439–444PubMedGoogle Scholar
  9. 9.
    Sutherland L, Singleton J, Sessions J et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 32:1071–1075CrossRefPubMedGoogle Scholar
  10. 10.
    Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity. Lancet 1:514CrossRefPubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • Bret J. Spier
    • 1
  • Scott B. Perlman
    • 2
  • Christine J. Jaskowiak
    • 2
  • Mark Reichelderfer
    • 1
  1. 1.Department of Gastroenterology and HepatologyUniversity of Wisconsin Hospital and Clinics in MadisonMadisonUSA
  2. 2.Department of RadiologyUniversity of Wisconsin Hospital and Clinics in MadisonMadisonUSA

Personalised recommendations